ImmunoID NeXT is the first platform to enable the comprehensive analysis of both a tumor and its microenvironment from a single sample. Providing genomic information for all ~20,000 genes, ImmunoID NeXT consolidates multiple oncology biomarker assays into one – maximizing the biological insights gained from a single sample. When specimens are limited, researchers must make difficult decisions regarding which biomarkers to analyze.
Figure 1: ImmunoID NeXT represents an end-to-end solution for immuno-oncology and all precision oncology applications. It combines the pioneering NeXT assay, sophisticated analytical engines, and quality support to provide researchers with the comprehensive immunogenomic data they need to drive their programs.
Specifically built for immuno-/precision oncology, Personalis NeXT Platform is used to investigate key areas of tumor biology; from elucidating mechanisms of tumor escape and detecting neoantigens, to identifying novel gene expression signatures and characterizing the immune repertoire. With these extensive capabilities, ImmunoID NeXT effectively consolidates multiple biomarker assays into one.
The unique design of the assay and analytical algorithms enables the delivery of critical tumor- and immune-related information including, but not limited to:
i) T-cell receptor (TCR) alpha & beta repertoire
ii) BCR heavy chain (BCRh) repertoire and isotype composition
iii) Neoantigen detection and neoantigen load
iv) Tumor mutational burden (TMB)
v) Microsatellite instability (MSI) characterization
vi) Human leukocyte antigens (HLA) typing, HLA and beta-2 microglobulin (B2M) somatic mutations, and HLA loss of heterozygosity (LOH)
vii) Tumor escape and resistance mechanisms
viii) Oncoviral detection